Virginia Alonso-Aguirre

Dr. Virginia Alonso-Aguirre


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2026 in Biology
Verified
Journal Article
Open access
PDF file
VAVirginia Alonso-Aguirre
Virginia Alonso-Aguirre
AEALBERTO SANCHEZ ESPINOSA
ALBERTO SANCHEZ ESPINOSA
JGJosé García-Rodríguez
José García-Rodríguez
ASAntonio David Lázaro Sánchez
Antonio David Lázaro Sánchez
Ginés Luengo-GilGinés Luengo-Gil
Ginés Luengo-Gil
Risk stratification in localised prostate cancer still relies mainly on clinical, pathological and genomic variables, whereas readily deployable tissue protein biomarkers remain insufficiently validated, particularly in patients treated with radiotherapy. This narrative review examines periostin (POSTN), mitogen-activated protein kinase 8 interacting protein 2 (MAPK8IP2/JIP2), cell division cycle-associated protein 3 (CDCA3) and non-SMC condensin II complex subunit G2 (NCAPG2) as illustrative candidates within a hypothesis-generating framework of potentially complementary biological processes. The review links the available evidence on these candidates to testable radiobiological hypotheses and specific experimental and clinical validation strategies. We searched PubMed on 25 October 2026 for publications dated from 1 January 2021 through 14 July 2026. We also included selected earlier publications. POSTN had the relatively strongest prostate-cancer tissue-level rationale, with stromal expression associated with adverse features and recurrence-related or metastatic biology. MAPK8IP2/JIP2 was associated with stress signalling, androgen-receptor-related states, and adverse features, but the evidence was mainly retrospective, transcriptomic, and experimental. CDCA3 was linked to cell-cycle and checkpoint regulation, whereas NCAPG2 was associated with chromosome organisation, malignancy, and STAT3/c-MYC-related stemness. However, no study identified in the literature reviewed demonstrated radiotherapy-specific predictive value, fractionation sensitivity, or androgen-deprivation benefit for any candidate. Future studies should use standardised compartment-specific immunohistochemistry, spatial assessment, patient-level model development, independent validation, comparison with clinical and genomic classifiers, and prespecified biomarker-by-treatment interaction analyses.